Validating survivin as a cancer therapeutic target.
Acquisition of the ability to evade cellular suicide, or apoptosis, is one of the master switches that contributes to cellular transformation and, ultimately, to invasive cancer. Much has been learned about the molecular organization of apoptotic pathways and their regulators, but the identification and validation of translational targets for apoptosis-based cancer therapy has posed a great challenge. Survivin is an attractive candidate for cancer therapy, so what is its potential applicability in the clinic?
Altieri
Dario C
DC
Department of Cancer Biology, LRB-428, University of Massachusetts Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, USA. dario.altieri@umassmed.edu
D000951:Antigens, Neoplasm; D017209:Apoptosis / Q000187:drug effects; D015853:Cysteine Proteinase Inhibitors / Q000502:physiology / Q000627:therapeutic use*; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000502:physiology / Q000627:therapeutic use*; D009363:Neoplasm Proteins; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000077022:Survivin
D000951:Antigens, Neoplasm; C107489:BIRC5 protein, human; D015853:Cysteine Proteinase Inhibitors; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin